60
Participants
Start Date
August 25, 2022
Primary Completion Date
July 31, 2028
Study Completion Date
July 31, 2030
Pembrolizumab
Pre-operative Pembrolizumab (200mg IV every 3 weeks) for 2 cycles
Lenvatinib
Pre-operative Lenvatinib (8 or 12mg PO once daily according to bodyweight \<60gk≥) for 6 weeks
Pembrolizumab and Lenvatinib
Pre-operative combination of pembrolizumab and lenvatinib at the standard doses and duration as per cohort 1 and 2
RECRUITING
Queen Elizabeth Hospital, Birmingham
RECRUITING
Addenbrooke's Hospital, Cambridge
NOT_YET_RECRUITING
Beatson West of Scotland Cancer Centre, Glasgow
NOT_YET_RECRUITING
St James's Hospital, Leeds
NOT_YET_RECRUITING
Clatterbridge Cancer Centre, Liverpool
RECRUITING
Hammersmith Hospital, London
RECRUITING
King's College Hospital, London
RECRUITING
Royal Free Hospital, London
NOT_YET_RECRUITING
The Christie NHS Foundation Trust, Manchester
RECRUITING
Freeman Hospital, Newcastle upon Tyne
NOT_YET_RECRUITING
Western General Hospital, Edinburgh
Merck Sharp & Dohme LLC
INDUSTRY
University College, London
OTHER